A late-breaking presentation at EHRA 2026 reaffirmed the safety and effectiveness of Boston Scientific’s FARAPULSE Pulsed Field Ablation (PFA) Platform.
One-year outcomes in 49 persistent atrial fibrillation (AF) patients treated with the FARAPULSE Pulsed Field Ablation Platform, using the FARAWAVE PFA Catheter, demonstrated favourable efficacy and safety outcomes, as well as predictable and efficient procedural length.
In line with previous data, results demonstrated a 65 per cent efficacy rate, defined as freedom from recurrence, repeat ablation or further antiarrhythmic drug use, and a low safety event rate, with no reports of stroke, oesophageal fistulas or pulmonary vein stenosis
Results follow last month’s CE mark approval for persistent atrial fibrillation. In Europe, the FARAPULSE PFA Platform is now approved for the treatment of persistent and paroxysmal AF, with the FARAPOINT catheter indicated for the treatment of right atrial flutter.
Angelo Auricchio is Chief Medical Officer for Rhythm Management EMEA at Boston Scientific.
Auricchio said: “The BEAT PERS-AF study builds on the safety and efficacy profile of the FARAPULSE Pulsed Field Ablation Platform in treating patients with persistent atrial fibrillation.
“These findings are consistent with prior studies, including the ADVANTAGE AF trial, and contribute to the growing body of clinical evidence supporting FARAPULSE.
“They reflect Boston Scientific’s continued commitment to advancing electrophysiology through robust science and delivering innovative, patient-focused solutions.”
